Betta Pharmaceuticals Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Public, Subsidiary
- Established
- 2003-01-07
- Employees
- 1.9K
- Market Cap
- -
- Website
- https://www.bettapharma.com
Clinical Trials
73
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (73 trials with phase data)• Click on a phase to view related trials
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
- Conditions
- NSCLCAdjuvant Drug TherapyEGFR
- Interventions
- First Posted Date
- 2025-09-18
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT07181499
- Locations
- 🇨🇳
The Cancer Center of The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06885840
- Locations
- 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳The First Hospital of Lanzhou University, Lanzhou, Gansu, China
🇨🇳Dongguan People's Hospital, Dongguan, Guangdong, China
A Phase I Study of CFT8919 in Patients With Advanced NSCLC
- Conditions
- Non-Small Cell Lung Cancer With EGFR Mutation
- Interventions
- Drug: Dose-Escalation (Phase Ia) CFT8919 capsuleDrug: Dose-Expansion (Phase Ib) CFT8919 capsuleDrug: Cohort-Expansion (Phase Ic) CFT8919 capsule
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 166
- Registration Number
- NCT06641609
- Locations
- 🇨🇳
浙江省杭州市拱墅区半山东路1号的英文翻译为： No. 1 Banshan East Road, Gongshu District, Hangzhou, Zhejiang Province, China, Hangzhou, Zhejiang, China
A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT06492525
- Locations
- 🇨🇳
The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
- Conditions
- Non-Small Cell Lung CancerEGFR Sensitive MutationAdjuvant Therapy
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 570
- Registration Number
- NCT06041776
- Locations
- 🇨🇳
Peking University International Hospital, Beijing, China
🇨🇳Jiangsu Cancer Hospital, Nanjing, China
🇨🇳Shanghai chest hospital, Shanghai, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 15
- Next
News
EyePoint Pharmaceuticals Raises $150 Million to Advance DURAVYU Phase 3 Trials for Retinal Diseases
EyePoint Pharmaceuticals announced a $150 million public offering to fund clinical development of DURAVYU for wet age-related macular degeneration and diabetic macular edema.
Angel Pharmaceuticals Receives China IND Approval for Soquelitinib Atopic Dermatitis Trial
Angel Pharmaceuticals received IND approval from China's NMPA to initiate a Phase 1b/2 clinical trial of soquelitinib for moderate-to-severe atopic dermatitis treatment.
C4 Therapeutics Announces 2025 Milestones for Oncology-Focused Degrader Medicines
C4 Therapeutics is set to advance clinical development of cemsidomide, with Phase 1 data expected in late 2025 for multiple myeloma and non-Hodgkin’s lymphoma.
EyePoint's DURAVYU Shows Promise in Phase 2 DME Trial
EyePoint Pharmaceuticals reported positive interim results from its Phase 2 VERONA trial of DURAVYU for diabetic macular edema (DME).